Evidence map›Paper›PMID 42530745›Full record

ArticleMagma (New York, N.Y.)2026

Differentiation between glioblastomas and solid brain metastases using amide proton transfer-weighted (APTw) MRI with and without fluid suppression.

Malte Knutsson, Tim Salomonsson, Anina Seidemo, Anna Rydelius, Xavier Saenz Sarda, Patrick Liebig, Mattias Belting, Johan Bengzon, Peter C M van Zijl, Linda Knutsson and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Magma (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Malte KnutssonDivision of Radiology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Tim SalomonssonDivision of Radiology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Anina SeidemoDivision of Radiology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Anna RydeliusDivision of Neurology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Xavier Saenz SardaDivision of Pathology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Patrick LiebigAdvanced Systems, Magnetic Resonance, Siemens Healthineers AG, Erlangen, Germany.
Mattias BeltingDivision of Oncology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Johan BengzonDivision of Neurosurgery, Department of Clinical Sciences, Kamprad Laboratory, Lund University, Skåne University Hospital, Lund, Sweden.
Peter C M van ZijlF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA.
Linda KnutssonF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA.
Pia C SundgrenDivision of Radiology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden. pia.sundgren@med.lu.se.ORCID http://orcid.org/0000-0001-9237-1236

Funding

Cancerfonden CAN 2024 24 3568Cancerfonden CAN 23 2937 Pj 01 HRegional research funds F 2022/0108Vetenskapsrådet 2019-01162Vetenskapsrådet VR 2023-02412
6 · The paper itself

Abstract

objectAccurate differentiation between glioblastomas (GBM) and solitary brain metastases (MET) is crucial for treatment planning. This study evaluated the ability of amide proton transfer-weighted (APTw) MRI with and without fluid suppression (FS) to distinguish between GBM and MET.

methodThirty-two patients with histopathologically confirmed GBM (n = 24) or MET (n = 8) were included. Post-processing included creation of APTw maps without FS, with patient-specific FS based on the patient's white matter values and with a fixed-factor FS. Regions of interest (ROIs) were segmented in the contrast-enhanced tumour, peritumoural oedema, necrosis and the normal-appearing white matter (NAWM). The min, max and mean signals were extracted for each ROI and normalised to NAWM, creating normalised APTw (nAPTw) values. Group differences were determined with t test and Mann-Whitney U test. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis.

resultsBoth FS methods significantly reduced nAPTw values in tumour regions. Patient-specific FS showed highest performance in distinguishing GBM from MET in the necrotic (AUC 0.921) and oedematous regions (AUC 0.698). Fixed FS provided minor to intermediate improvements.

conclusionPatient-specific fluid suppression increased the diagnostic performance of APTw imaging in differentiating GBM from MET, particularly in oedematous and necrotic regions.

Indexed as

Amide proton transfer-weighted imagingFluid suppressionGlioblastomaGliomaMetastases

Identifiers

PMID42530745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.